ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Sun, Yongkun; Zhang, Wen; Bi, Xinyu; Yang, Zhengqiang; Tang, Yu; Jiang, Liming; Bi, Feng; Chen, Minshan; Cheng, Shuqun; Chi, Yihebali; Han, Yue; Huang, Jing; Huang, Zhen; Ji, Yuan; Jia, Liqun; Jiang, Zhichao; Jin, Jing; Jin, Zhengyu; Li, Xiao; Li, Zhiyu; Liang, Jun; Liu, Lianxin; Liu, Yunpeng; Lu, Yinying; Lu, Shichun; Meng, Qinghua; Niu, Zuoxing; Pan, Hongming; Qin, Shukui; Qu, Wang; Shao, Guoliang; Shen, Feng; Song, Tianqiang; Song, Yan; Tao, Kaishan; Tian, Aiping; Wang, Jianhua复旦大学; 北京大学; 吉林大学; 青岛大学; 山东省医学科学院; 哈尔滨医科大学; 浙江大学; 中国人民解放军第四军医大学; 中国医科大学; 中国医学科学院; 中山大学; 中国科学院研究生院; 中国医学科学院北京协和医院; 6; 1; 5
Liver Cancer2022-6DOI: 10.1159/000521596
16被引28閱讀
引用收藏
分享

摘要

Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.

學科與關鍵詞

關鍵詞
Chinese interdisciplinary expertsHepatocellular carcinomaMolecular targeted therapyConsensus
相關
載入中…

文獻載入失敗,請重試

重試

發表資訊

論文狀態
公開發表
期刊
Liver Cancer
發表日期
2022-06
卷期
第 11 卷, 第 3 期
頁碼
192-208
DOI
10.1159/000521596
期刊等級
1区
成果收錄
SCIE
資助標註
State Key Project on Infection Diseases of China [2017ZX10201021-007-003]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2017-12M-4-002]; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences [2019PT310026]; Sanming Project of Medicine in Shenzhen [SZSM202011010]; Capital Health Research and Development of Special [2018-1-4021]

作者

  • S

    Sun, Yongkun (第一作者)

    chinese acad med sci · peking union med coll

  • Z

    Zhang, Wen

    chinese acad med sci · peking union med coll

查看全部 64 位作者收起作者
  • B

    Bi, Xinyu

    chinese acad med sci · peking union med coll

  • Y

    Yang, Zhengqiang

    chinese acad med sci · peking union med coll

  • T

    Tang, Yu

    chinese acad med sci · peking union med coll

  • J

    Jiang, Liming

    chinese acad med sci · peking union med coll

  • B

    Bi, Feng

  • C

    Chen, Minshan

    sun yat sen univ

  • C

    Cheng, Shuqun

    6

  • C

    Chi, Yihebali

    chinese acad med sci · peking union med coll

  • H

    Han, Yue

    chinese acad med sci · peking union med coll

  • H

    Huang, Jing

    chinese acad med sci · peking union med coll

  • H

    Huang, Zhen

    chinese acad med sci · peking union med coll

  • J

    Ji, Yuan

    fudan univ

  • J

    Jia, Liqun

    china japan friendship hosp

  • J

    Jiang, Zhichao

    chinese acad med sci · peking union med coll

  • J

    Jin, Jing

    chinese acad med sci · peking union med coll

  • J

    Jin, Zhengyu

    peking union med coll hosp

  • L

    Li, Xiao

    chinese acad med sci · peking union med coll

  • L

    Li, Zhiyu

    chinese acad med sci · peking union med coll

  • L

    Liang, Jun

    peking univ

  • L

    Liu, Lianxin

    1 · univ sci & technol china

  • L

    Liu, Yunpeng

    1 · china med univ

  • L

    Lu, Yinying

    5 · chinese peoples liberat army gen hosp

  • L

    Lu, Shichun

    1 · chinese peoples liberat army pla gen hosp

  • M

    Meng, Qinghua

    capital med univ

  • N

    Niu, Zuoxing

  • P

    Pan, Hongming

    zhejiang univ

  • Q

    Qin, Shukui

    nanjing bayi hosp

  • Q

    Qu, Wang

    chinese acad med sci · peking union med coll

  • S

    Shao, Guoliang

    univ chinese acad sci

  • S

    Shen, Feng

  • S

    Song, Tianqiang

    tianjin med univ canc inst & hosp

  • S

    Song, Yan

    chinese acad med sci · peking union med coll

  • T

    Tao, Kaishan

    fourth mil med univ

  • T

    Tian, Aiping

    chinese acad med sci · peking union med coll

  • W

    Wang, Jianhua

    fudan univ

  • W

    Wang, Wenling

  • W

    Wang, Zhe

    fourth mil med univ

  • W

    Wu, Liqun

    qingdao univ

  • X

    Xia, Feng

  • X

    Xing, Baocai

  • X

    Xu, Jianming

  • X

    Xue, Huadan

    peking union med coll hosp

  • Y

    Yan, Dong

    chinese acad med sci · peking union med coll

  • Y

    Yang, Lin

    chinese acad med sci · peking union med coll

  • Y

    Ying, Jianming

  • Y

    Yun, Jingping

  • Z

    Zeng, Zhaochong

  • Z

    Zhang, Xuewen

  • Z

    Zhang, Yanqiao

  • Z

    Zhang, Yefan

    chinese acad med sci · peking union med coll

  • Z

    Zhao, Jianjun

    chinese acad med sci · peking union med coll

  • Z

    Zhou, Jianguo

    chinese acad med sci · peking union med coll

  • Z

    Zhu, Xu

  • Z

    Zou, Yinghua

  • D

    Dong, Jiahong

  • F

    Fan, Jia

  • L

    Lau, Wan Yee

  • S

    Sun, Yan

    chinese acad med sci · peking union med coll

  • Y

    Yu, Jinming

  • Z

    Zhao, Hong

    chinese acad med sci · peking union med coll

  • Z

    Zhou, Aiping

    chinese acad med sci · peking union med coll

  • C

    Cai, Jianqiang

    chinese acad med sci · peking union med coll

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417